Clinical Trials Logo

Clinical Trial Summary

A minority of patients with colorectal liver metastases and hepatobiliary cancer (primary liver cancer) are candidates for surgery, but there are no curative treatment options for these patients. Their median survival time is 3 to 12 months. Stereotactic radiation (SRT) (highly conformal radiotherapy (CRT)) is a treatment option for these patients with unresectable liver cancer, now possible due to improvements in our ability to localize and immobilize liver tumors and an improved understanding of the partial liver volume tolerance to radiation. SRT should permit liver tumors to be treated to tumorcidal doses while sparing the uninvolved liver, decreasing the risk of treatment related normal tissue toxicity. With such conformal radiation, it is possible to deliver radiation in fewer fractions than traditionally required, which should be more convenient for patients. In this study, CRT will be delivered during shallow breathing or breath hold to minimize organ motion due to breathing, decreasing the volume of normal liver that must be irradiated.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00152906
Study type Interventional
Source University Health Network, Toronto
Contact
Status Completed
Phase Phase 1/Phase 2
Start date July 2003
Completion date July 10, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Not yet recruiting NCT03592550 - The eValuation of Image Guidance of Stereotactic Body Radiotherapy Using Ultrasound: Assessment in Liver
Not yet recruiting NCT02521129 - A New Track Ablation Device for Liver Biopsy: A Feasibility Study Phase 1/Phase 2
Not yet recruiting NCT02168608 - Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy N/A
Enrolling by invitation NCT01465425 - Extracolonic Findings on Computed Tomography (CT) Colonography
Active, not recruiting NCT01177007 - Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors Phase 2
Completed NCT00788697 - SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization Phase 3
Recruiting NCT01564810 - Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Phase 4
Completed NCT00094003 - Study of NS-9 in Patients With Liver Metastases Phase 1
Terminated NCT00051532 - Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma N/A
Completed NCT00001587 - A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver Phase 1
Completed NCT00222664 - Qidong Hepatitis B Intervention Study Phase 4
Recruiting NCT04518852 - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC Phase 2
Completed NCT03289273 - Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Terminated NCT03349255 - Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma Phase 1
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Recruiting NCT03715517 - Spinal Anesthesia For Enhanced Recovery After Liver Surgery N/A
Terminated NCT03685591 - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Phase 1
Terminated NCT01744054 - Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization Phase 1
Active, not recruiting NCT02969096 - Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma Phase 2